

Docket No.: 217408US0CONT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF: :

Chika NAKANISHI et al. : ATTN: APPLICATION DIVISION

SERIAL NO: NEW APPLICATION :

FILED: HEREWITH :

FOR: DIHYDROPYRIDINE DERIVATIVES

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Prior to examination on the merits, please amend the above-identified application as follows.

IN THE SPECIFICATION

Page 1, before line 1, please insert

--This application is a Continuation of International Application Serial No.

PCT/JP00/04105, filed on June 22, 2000--

IN THE CLAIMS

Please amend the claims as follows.

--16. (Amended) An N-type calcium channel antagonist comprising a dihydropyridine derivative or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

17. (Amended) A therapeutic agent comprising the dihydropyridine derivative or a pharmaceutically acceptable salt thereof according to claim 1 as the active ingredient, for any of acute stage of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, pain caused by thromboangiitis obliterans, postoperative pain, migraine, visceral pain, bronchial asthma, unstable angina, irritable colitis and withdrawal symptoms after addiction to drugs.

18. (Amended) A therapeutic agent comprising the dihydropyridine derivative or a pharmaceutically acceptable salt thereof according to claim 3 as the active ingredient, for any of acute stage of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, pain caused by thromboangiitis obliterans, postoperative pain, migraine, visceral pain, bronchial asthma, unstable angina, irritable colitis and withdrawal symptoms after addiction to drugs.

19. (Amended) A therapeutic agent comprising the dihydropyridine derivative or a pharmaceutically acceptable salt thereof according to claim 12 as the active ingredient, for any of acute stage of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, pain caused by thromboangiitis obliterans, postoperative pain, migraine, visceral pain, bronchial asthma, unstable angina, irritable colitis and withdrawal symptoms after addiction to drugs.

20. (Amended) A pharmaceutical composition comprising any of dihydropyridine compounds and pharmaceutically acceptable salts thereof according to claim as an active ingredient.--

Please add the following new claim.

--21. (New) A method of treating acute stage of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, pain caused by thromboangiitis obliterans, postoperative pain, migraine, visceral pain, bronchial asthma, unstable angina, irritable colitis, or withdrawal symptoms after addiction to drugs, comprising administering an effective amount of the dihydropyridine compound or a pharmaceutically acceptable salt thereof to a subject in need thereof.--

REMARKS

Claims 1-21 are pending in this application.


This application is a Continuation of International Application Serial No. PCT/JP00/04105, filed on June 22, 2000.

Claims 16-20 have been amended to depend from Claim 1 only. Newly added Claim 21 is supported by the specification at pages 3-128 and by original Claims 1-20. No new matter is believed to have been added to this application by these amendments.

Applicants submit that the present application is ready for examination on the merits. Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

James J. Kelly, Ph.D.
Registration No. 41,504



22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 11/98)

IN THE CLAIMS

Please amend the claims as follows.

--16. (Amended) An N-type calcium channel antagonist comprising a dihydropyridine derivative or a pharmaceutically acceptable salt thereof according to claim 1 [any of claims 1 to 15] as an active ingredient.

17. (Amended) A therapeutic agent comprising the dihydropyridine derivative or a pharmaceutically acceptable salt thereof according to claim 1 [or 2] as the active ingredient, for any of acute stage of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, pain caused by thromboangiitis obliterans, postoperative pain, migraine, visceral pain, bronchial asthma, unstable angina, irritable colitis and withdrawal symptoms after addiction to drugs.

18. (Amended) A therapeutic agent comprising the dihydropyridine derivative or a pharmaceutically acceptable salt thereof according to claim 3 [any of claims 3 to 11] as the active ingredient, for any of acute stage of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, pain caused by thromboangiitis obliterans, postoperative pain, migraine, visceral pain, bronchial asthma, unstable angina, irritable colitis and withdrawal symptoms after addiction to drugs.

19. (Amended) A therapeutic agent comprising the dihydropyridine derivative or a pharmaceutically acceptable salt thereof according to claim 12 [any of claims 12 to 15] as the active ingredient, for any of acute stage of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, pain caused by thromboangiitis obliterans, postoperative pain, migraine, visceral pain, bronchial asthma, unstable angina, irritable colitis and withdrawal symptoms after addiction to drugs.

20. (Amended) A pharmaceutical composition comprising any of dihydropyridine compounds and pharmaceutically acceptable salts thereof according to claim 1 [any of claims 1 to 15] as an active ingredient.--

--21. (New)--